Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: a modelling study.

Simon J, Harmer CJ, Kingslake J, Dawson GR, Dourish CT, Goodwin GM.

Evid Based Ment Health. 2019 Nov;22(4):145-152. doi: 10.1136/ebmental-2019-300109. Epub 2019 Sep 27.

PMID:
31562131
2.

Interoception and disordered eating: A systematic review.

Martin E, Dourish CT, Rotshtein P, Spetter MS, Higgs S.

Neurosci Biobehav Rev. 2019 Dec;107:166-191. doi: 10.1016/j.neubiorev.2019.08.020. Epub 2019 Aug 24. Review.

PMID:
31454626
3.

Predicting treatment response to antidepressant medication using early changes in emotional processing.

Browning M, Kingslake J, Dourish CT, Goodwin GM, Harmer CJ, Dawson GR.

Eur Neuropsychopharmacol. 2019 Jan;29(1):66-75. doi: 10.1016/j.euroneuro.2018.11.1102. Epub 2018 Nov 22.

4.

Top-down guidance of attention to food cues is enhanced in individuals with overweight/obesity and predicts change in weight at one-year follow up.

Kaisari P, Kumar S, Hattersley J, Dourish CT, Rotshtein P, Higgs S.

Int J Obes (Lond). 2019 Sep;43(9):1849-1858. doi: 10.1038/s41366-018-0246-3. Epub 2018 Nov 21.

5.

Associations Between Core Symptoms of Attention Deficit Hyperactivity Disorder and Both Binge and Restrictive Eating.

Kaisari P, Dourish CT, Rotshtein P, Higgs S.

Front Psychiatry. 2018 Mar 29;9:103. doi: 10.3389/fpsyt.2018.00103. eCollection 2018.

6.

The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial.

Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, Morriss R, Brown S, Guo B, Dourish CT, Ruhé HG, Lever AG, Veltman DJ, van Schaik A, Deckert J, Reif A, Stäblein M, Menke A, Gorwood P, Voegeli G, Pérez V, Browning M.

Trials. 2017 Nov 23;18(1):558. doi: 10.1186/s13063-017-2247-2.

7.

Multidisciplinary approaches to the study of eating disorders and obesity: Recent progress in research and development and future prospects.

Dourish CT, Clifton PG.

J Psychopharmacol. 2017 Nov;31(11):1383-1387. doi: 10.1177/0269881117740779. No abstract available.

PMID:
29157103
8.

The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers.

Thomas JM, Dourish CT, Tomlinson J, Hassan-Smith Z, Hansen PC, Higgs S.

Psychopharmacology (Berl). 2018 Jan;235(1):257-267. doi: 10.1007/s00213-017-4764-9. Epub 2017 Oct 28.

9.

Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies.

Higgs S, Spetter MS, Thomas JM, Rotshtein P, Lee M, Hallschmid M, Dourish CT.

J Psychopharmacol. 2017 Nov;31(11):1460-1474. doi: 10.1177/0269881117736917. Epub 2017 Oct 26. Review.

10.

Attention Deficit Hyperactivity Disorder (ADHD) and disordered eating behaviour: A systematic review and a framework for future research.

Kaisari P, Dourish CT, Higgs S.

Clin Psychol Rev. 2017 Apr;53:109-121. doi: 10.1016/j.cpr.2017.03.002. Epub 2017 Mar 6. Review.

11.

Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies.

Koychev I, Joyce D, Barkus E, Ettinger U, Schmechtig A, Dourish CT, Dawson GR, Craig KJ, Deakin JF.

Transl Psychiatry. 2016 May 17;6:C. doi: 10.1038/tp.2016.64.

12.

Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.

Downey D, Dutta A, McKie S, Dawson GR, Dourish CT, Craig K, Smith MA, McCarthy DJ, Harmer CJ, Goodwin GM, Williams S, Deakin JF.

Eur Neuropsychopharmacol. 2016 Jun;26(6):994-1003. doi: 10.1016/j.euroneuro.2016.03.006. Epub 2016 Apr 28.

PMID:
27133029
13.

Test-retest reliability and effects of repeated testing and satiety on performance of an Emotional Test Battery.

Thomas JM, Higgs S, Dourish CT.

J Clin Exp Neuropsychol. 2016;38(4):416-33. doi: 10.1080/13803395.2015.1121969. Epub 2015 Dec 24.

14.

Investigating virtual reality navigation in amnestic mild cognitive impairment using fMRI.

Migo EM, O'Daly O, Mitterschiffthaler M, Antonova E, Dawson GR, Dourish CT, Craig KJ, Simmons A, Wilcock GK, McCulloch E, Jackson SH, Kopelman MD, Williams SC, Morris RG.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2016;23(2):196-217. doi: 10.1080/13825585.2015.1073218. Epub 2015 Aug 3.

PMID:
26234803
15.
16.

Satiation attenuates BOLD activity in brain regions involved in reward and increases activity in dorsolateral prefrontal cortex: an fMRI study in healthy volunteers.

Thomas JM, Higgs S, Dourish CT, Hansen PC, Harmer CJ, McCabe C.

Am J Clin Nutr. 2015 Apr;101(4):697-704. doi: 10.3945/ajcn.114.097543. Epub 2015 Jan 21.

PMID:
25833968
17.

Alterations in working memory networks in amnestic mild cognitive impairment.

Migo EM, Mitterschiffthaler M, O'Daly O, Dawson GR, Dourish CT, Craig KJ, Simmons A, Wilcock GK, McCulloch E, Jackson SH, Kopelman MD, Williams SC, Morris RG.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2015;22(1):106-27. doi: 10.1080/13825585.2014.894958. Epub 2014 Mar 12.

PMID:
24617815
18.

Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers.

Thomas JM, Dourish CT, Tomlinson JW, Hassan-Smith Z, Higgs S.

Psychopharmacology (Berl). 2014 Jun;231(12):2449-59. doi: 10.1007/s00213-013-3409-x. Epub 2014 Jan 10.

PMID:
24408211
19.

The effects of ketamine and risperidone on eye movement control in healthy volunteers.

Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, William Deakin JF, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SC, Ettinger U.

Transl Psychiatry. 2013 Dec 10;3:e334. doi: 10.1038/tp.2013.109.

20.

Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia.

Dourish CT, Dawson GR.

Biomark Med. 2014;8(1):5-8. doi: 10.2217/bmm.13.89. No abstract available.

21.

Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate.

Diaper A, Rich AS, Wilson SJ, Craig K, Dourish CT, Dawson GR, Nutt DJ, Bailey JE.

Hum Psychopharmacol. 2013 Nov;28(6):562-75.

PMID:
23955418
22.

Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR, Deakin JF, Dourish CT, Koychev I, McMullen K, Migo EM, Perry C, Wilkinson L, Morris R, Williams SC, Ettinger U.

Psychopharmacology (Berl). 2013 May;227(2):331-45. doi: 10.1007/s00213-013-2973-4. Epub 2013 Feb 22.

PMID:
23430159
23.

Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans.

Harmer CJ, Dawson GR, Dourish CT, Favaron E, Parsons E, Fiore M, Zucchetto M, Bifone A, Poggesi I, Fernandes S, Alexander RC, Goodwin GM.

J Psychopharmacol. 2013 May;27(5):435-43. doi: 10.1177/0269881112472558. Epub 2013 Feb 12.

PMID:
23407644
24.

The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.

Diaper A, Papadopoulos A, Rich AS, Dawson GR, Dourish CT, Nutt DJ, Bailey JE.

Hum Psychopharmacol. 2012 Nov;27(6):540-8. doi: 10.1002/hup.2261. Epub 2012 Oct 2.

PMID:
23027657
25.

Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.

Diaper A, Osman-Hicks V, Rich AS, Craig K, Dourish CT, Dawson GR, Nutt DJ, Bailey JE.

J Psychopharmacol. 2013 Feb;27(2):135-45. doi: 10.1177/0269881112443742. Epub 2012 Apr 19.

PMID:
22516666
26.

A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study.

Koychev I, McMullen K, Lees J, Dadhiwala R, Grayson L, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, Ettinger U, Wilkinson L, Williams S, Deakin JF, Barkus E.

Eur Neuropsychopharmacol. 2012 Jul;22(7):469-81. doi: 10.1016/j.euroneuro.2011.10.005. Epub 2011 Dec 3.

PMID:
22137565
27.

Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD).

Bailey JE, Dawson GR, Dourish CT, Nutt DJ.

J Psychopharmacol. 2011 Sep;25(9):1192-8. doi: 10.1177/0269881111408455. Review.

PMID:
21994314
28.

Special issue on CNS experimental medicine.

Dawson GR, Dourish CT, Goodwin GM.

J Psychopharmacol. 2011 Sep;25(9):1145-7. doi: 10.1177/0269881111415342. No abstract available.

PMID:
21994313
29.

Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.

Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, Dourish CT, Dawson GR, Nutt DJ.

J Psychopharmacol. 2011 Sep;25(9):1199-206. doi: 10.1177/0269881111400650. Epub 2011 May 9.

PMID:
21555331
30.

Validation of experimental medicine methods in psychiatry: the P1vital approach and experience.

Dawson GR, Craig KJ, Dourish CT.

Biochem Pharmacol. 2011 Jun 15;81(12):1435-41. doi: 10.1016/j.bcp.2011.03.013. Epub 2011 Apr 1. Review.

PMID:
21440531
31.

Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.

Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, Cowen PJ, Goodwin GM.

J Psychopharmacol. 2011 Sep;25(9):1159-67. doi: 10.1177/0269881110376689. Epub 2010 Jul 21.

PMID:
20660010
32.

The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.

Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT, Dawson GR, Wilding JP.

J Psychopharmacol. 2010 Jan;24(1):99-109. doi: 10.1177/0269881108095195. Epub 2008 Aug 28.

PMID:
18755818
33.

Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.

Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Jordan AM, Knight AR, Lerpiniere J, Misra A, Pratt RM, Roffey J, Stratton GC, Upton R, Weiss SM, Williamson DS.

Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. doi: 10.1016/j.bmcl.2008.03.072. Epub 2008 Mar 30.

PMID:
18411049
34.

Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.

Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Giles PR, Jordan AM, Knight AR, Lawrence A, Lerpiniere J, Misra A, Pratt RM, Todd RS, Upton R, Weiss SM, Williamson DS.

Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. doi: 10.1016/j.bmcl.2008.03.076. Epub 2008 Mar 30.

PMID:
18407496
35.

Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.

Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS.

Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. doi: 10.1016/j.bmcl.2008.03.075. Epub 2008 Mar 30.

PMID:
18406614
36.

Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse.

Dalton GL, Lee MD, Kennett GA, Dourish CT, Clifton PG.

Psychopharmacology (Berl). 2006 Mar;185(1):45-57. Epub 2006 Feb 10.

PMID:
16470405
37.

Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.

Adams DR, Bentley JM, Benwell KR, Bickerdike MJ, Bodkin CD, Cliffe IA, Dourish CT, George AR, Kennett GA, Knight AR, Malcolm CS, Mansell HL, Misra A, Quirk K, Roffey JR, Vickers SP.

Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. Epub 2005 Oct 27.

PMID:
16257207
38.

Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.

Röver S, Adams DR, Bénardeau A, Bentley JM, Bickerdike MJ, Bourson A, Cliffe IA, Coassolo P, Davidson JE, Dourish CT, Hebeisen P, Kennett GA, Knight AR, Malcolm CS, Mattei P, Misra A, Mizrahi J, Muller M, Porter RH, Richter H, Taylor S, Vickers SP.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3604-8.

PMID:
15975787
39.

Tonic regulation of satiety by 5-HT receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies?

Lee MD, Somerville EM, Kennett GA, Dourish CT, Clifton PG.

Eur J Neurosci. 2004 Jun;19(11):3017-25.

PMID:
15182309
40.

Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice.

Lee MD, Somerville EM, Kennett GA, Dourish CT, Clifton PG.

Psychopharmacology (Berl). 2004 Oct;176(1):39-49. Epub 2004 May 8.

PMID:
15138762
41.

Serotonin receptor ligands and the treatment of obesity.

Vickers SP, Dourish CT.

Curr Opin Investig Drugs. 2004 Apr;5(4):377-88. Review.

PMID:
15134278
42.

Indoline derivatives as 5-HT(2C) receptor agonists.

Bentley JM, Adams DR, Bebbington D, Benwell KR, Bickerdike MJ, Davidson JE, Dawson CE, Dourish CT, Duncton MA, Gaur S, George AR, Giles PR, Hamlyn RJ, Kennett GA, Knight AR, Malcolm CS, Mansell HL, Misra A, Monck NJ, Pratt RM, Quirk K, Roffey JR, Vickers SP, Cliffe IA.

Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.

PMID:
15081042
43.

mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes.

Dalton GL, Lee MD, Kennett GA, Dourish CT, Clifton PG.

Neuropharmacology. 2004 Apr;46(5):663-71.

PMID:
14996544
44.

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.

Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R, Dourish CT.

Neurology. 2003 Dec 9;61(11 Suppl 6):S101-6.

PMID:
14663021
45.

Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation.

Weiss SM, Whawell E, Upton R, Dourish CT.

Neurology. 2003 Dec 9;61(11 Suppl 6):S88-93. Review.

PMID:
14663018
46.

Oral administration of the 5-HT2Creceptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia.

Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT, Kennett GA.

Psychopharmacology (Berl). 2003 May;167(3):274-80. Epub 2003 Apr 11.

PMID:
12690422
47.

Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA.

Psychopharmacology (Berl). 2003 Apr;167(1):103-11. Epub 2003 Mar 11.

PMID:
12632249
48.

5-HT1B receptor knockout mice show a compensatory reduction in 5-HT2C receptor function.

Clifton PG, Lee MD, Somerville EM, Kennett GA, Dourish CT.

Eur J Neurosci. 2003 Jan;17(1):185-90.

PMID:
12534984
49.

5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253.

Lee MD, Kennett GA, Dourish CT, Clifton PG.

Psychopharmacology (Berl). 2002 Oct;164(1):49-60. Epub 2002 Jul 19.

PMID:
12373419
50.

Serotonin 2C receptor agonists and the behavioural satiety sequence in mice.

Hewitt KN, Lee MD, Dourish CT, Clifton PG.

Pharmacol Biochem Behav. 2002 Apr;71(4):691-700.

PMID:
11888560

Supplemental Content

Loading ...
Support Center